Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched historical control study along with single arm clinical trial

Peer Review reports

Original Submission
29 Jun 2020	Submitted	Original manuscript
28 Jul 2020	Reviewed	Reviewer Report
28 Aug 2020	Reviewed	Reviewer Report
8 Oct 2020	Author responded	Author comments - Seonyoung Park
Resubmission - Version 2
8 Oct 2020	Submitted	Manuscript version 2
2 Nov 2020	Reviewed	Reviewer Report
6 Nov 2020	Author responded	Author comments - Seonyoung Park
Resubmission - Version 3
6 Nov 2020	Submitted	Manuscript version 3
Publishing
11 Nov 2020	Editorially accepted
26 Nov 2020	Article published	10.1186/s12885-020-07629-z

Back to article page